Venous thromboembolism is a major cause of morbidity and mortality in hospitalized patients.
Approximately 100,000 to 200,000 patients die every year from venous or pulmonary thromboembolic events. Routine screening for evidence of venous thromboembolisms is expensive and impractical. The most effective method of reducing the risk of venous thromboembolism is by prophylactic administration of effective, safe, and simple anticoagulation drugs in high-risk patients. Prophylactic regimens consisting of unfractionated heparin or warfarin require laboratory monitoring and increase costs. Structurally, tinzaparin is an enzymatic depolymerization of heparin.